Economic evaluation of typhoid vaccination in a prolonged typhoid outbreak setting: The case of Kasese district in Uganda. Issue 17 (21st April 2015)

• Record Type: Journal Article
• Authors: Carias, Cristina; Walters, Maroya Spalding; Wefula, Edward; Date, Kashmira A.; Swerdlow, David L.; Vijayaraghavan, Maya; Mintz, Eric
• Is Part Of: Vaccine. Volume 33:Issue 17(2015)
• Page Start: 2079
• Page End: 2085
• Publication Date: 2015-04-21
• Subjects: Typhoid -- Typhoid vaccination -- Uganda -- Cost-effectiveness; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2015.02.027
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Background: Vaccination has been increasingly promoted to help control epidemic and endemic typhoid fever in high-incidence areas. Despite growing recognition that typhoid incidence in some areas of sub-Saharan Africa is similar to high-incidence areas of Asia, no large-scale typhoid vaccination campaigns have been conducted there. We performed an economic evaluation of a hypothetical one-time, fixed-post typhoid vaccination campaign in Kasese, a rural district in Uganda where a large, multi-year outbreak of typhoid fever has been reported. Methods: We used medical cost and epidemiological data retrieved on-site and campaign costs from previous fixed-post vaccination campaigns in Kasese to account for costs from a public sector health care delivery perspective. We calculated program costs and averted disability-adjusted life years (DALYs) and medical costs as a result of vaccination, to calculate the cost of the intervention per DALY and case averted. Results: Over the 3 years of projected vaccine efficacy, a one-time vaccination campaign was estimated to avert 1768 (90%CI: 684–4431) typhoid fever cases per year and a total of 3868 (90%CI: 1353–9807) DALYs over the duration of the immunity conferred by the vaccine. The cost of the intervention per DALY averted was US$ 484 (90%CI: 18–1292) and per case averted US$ 341 (90%CI: 13–883). Conclusion: We estimated the vaccination campaign in this setting to be highly cost-effective, according to WHO's cost-effective guidelines. Results may be applicable to other African settings with similar high disease incidence estimates.